Recipharm completed the acquisition of Mitim for $75m.

Recipharm, a contract development and manufacturing organisation in the pharmaceutical industry, completed the acquisition of Mitim, a provider of injectable beta-lactam products, for $75m. “This acquisition is very exciting for Recipharm and represents an important step in our consolidation of the CDMO industry. The transaction also cements our leading position in beta-lactam production and provides Recipharm not only with additional scale but also opportunities to realise commercial and operational synergies as we combine it with our existing Italian business," Thomas Eldered, Recipharm CEO.